LBA67 TRAMUNE, a phase Ib study combining trabectedin and durvalumab, results of the expansion cohort in patients with advanced pretreated soft tissue sarcomas

M Toulmonde,K Bourcier,M Brahmi,I.L Ray-Coquard,S Mothes,A Italiano,A Floquet,S Croce,J-Y Blay,M Kind,M Pulido,C Chakiba,S Mathoulin-Pélissier,S Cousin,R Perret,S Albert,A Bessede,E Toulza,A Giraud

doi:10.1016/j.annonc.2020.08.2308

LBA67 TRAMUNE, a phase Ib study combining trabectedin and durvalumab, results of the expansion cohort in patients with advanced pretreated soft tissue sarcomas

M Toulmonde, K Bourcier + Show 17 more

Open Access

https://doi.org/10.1016/j.annonc.2020.08.2308

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2020
Citations: 4	License type: publisher-specific-oa

Affiliation: Institut Bergonié, Centre Léon Bérard

#Expansion Cohort In Patients #PDL1 Inhibitor Durvalumab + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Trabectedin (T) activity is partly mediated by targeting tumor associated macrophages. We report results of a multicenter phase Ib study assessing safety and preliminary efficacy of T combined with the PDL1 inhibitor durvalumab (D) in patients (pts) with unresectable or metastatic STS and relapsed OC, focusing on the STS expansion cohort.

Full Text